The aim of the present study is to find the effectiveness of reported phytocompounds from Coccinia grandis fruits against Alzheimer's disease. Acetylcholinesterase is an important target in the treatment of Alzheimer's disease and it was taken as a receptor for this study. The reported phytocompounds were taken as ligand molecules and the 3D structure of human acetylcholinesterase was retrieved from PDB database. The 3D structure of synthetic drug and reported phytocompounds were obtained from Pub Chem database. Docking studies were performed using Glide (a Schrodinger module). From the results, it was observed that the phytocompounds β-Sitosterol (-8.70 Kcal/mol), Pectin (-7.82 Kcal/mol), Retinol (-7.24 Kcal/mol) and Taraxerone (-6.40 Kcal/mol) had better glide score than the synthetic drug rivastigmine (-5.6 Kcal/mol). Hence, it is suggested that intake of Coccinia grandis fruits can be used to reduce the severity and progress of Alzheimer's disease.
INTRODUCTION
Alzheimer's disease (AD) is the common form of dementia and there were about 25 million persons affected with AD worldwide out of which 4.5 million belongs to United States. It is expected to increase about 114 million by the year 2050 1, 2 . Malfunction of several biochemical pathways in elderly people lead to Alzheimer's disease. Cholinergic hypothesis has been the most successful approach to deal with this problem 3, 4 . Acetylcholine (ACh), an organic substance involved in the transfer of signals in brain, is hydrolyzed into choline and acetyl group which is catalyzed by acetylcholinesterase enzyme (AChE) 5 . The synthesized ACh gets accumulated in the vesicles and released into the synaptic cleft thereby regulates neurotransmission. Increasing the level of ACh in brain with acetylcholinesterase inhibitors like rivastigmine, galantamine, tacrine and donepazil is the key approach to treat AD 6 . These drugs have several side effects like gastrointestinal disturbances and problem associated with bioavailability 7, 8 . Hence there is an urge for finding better inhibitor for acetylcholinesterase from natural source to treat AD without any adverse effects. Coccinia grandis is commonly known as Ivy gourd which belongs to Cucurbitaceae family used in Indian traditional medicinal system 9 . The fruit has been used to treat leprosy, fever, asthma, bronchitis and jaundice dysentery, vomiting, mouth ulcers, diabetics, gastrointestinal disturbances and bronchitis. They possess various pharmacological activities such as antimicrobial 10 , hepatoprotective 11 , wound healing 12 , anthelmintic 13 antitussive 14 , antioxidant 15 and hypoglycemic 16 . The present study employs an in silico docking approach to understand the mechanism of natural compounds reported from Coccinia grandis fruit using GLIDE against AD. The docked phytocompounds were compared with the synthetic drug rivastigmine to find the efficacy of the phytocompounds.
MATERIALS AND METHODS

Retrieval of protein structure
The 3D structure of the selected Human acetylcholinesterase was retrieved from the Protein Data Bank (PDB), is a repository for the 3D structural data of large biological molecules, such as proteins and nucleic acids 17 .
Binding site prediction
The site binding of the receptor acetylcholinesterase was identified using CASTp server. It is a pictorial database which shows the molecule that make up of the structure (i.e. protein chains, ligands and metal ions) and schematic diagrams of their interactions. The PDB ID of the target protein was given as input.
Preparation of ligand structures
The reported phytocompounds of Coccinia grandis fruit used for docking analysis were selected from literature. The structures of the phytocompounds and synthetic drug were retrieved from Pub Chem database in the sdf file format.
Docking analysis
Docking analysis was carried out for the target protein acetylcholinesterase with the selected phytocompounds and the synthetic drug using GLIDE (a Schrodinger module) software 18 .
RESULTS
Complex structure of human acetylcholinesterase and binding site prediction
The 3D structure of human acetylcholinesterase was retrieved from the Protein Data Bank (PDB ID: 1B41) and viewed using PyMOL (Figure 1 ). The sequence length of the protein is 539 amino acids and the resolution of the structure is 2.76 Å 19 . PRO 
Structure of the ligand molecules
The structures of the phytocompounds and synthetic drug were obtained from Pub Chem and listed in Table 1 . The 3D structures of the compounds were docked with the target protein human acetylcholinesterase using GLIDE.
Docking analysis
In the present study, 4 major compounds reported in Coccinia grandis fruit were docked with the 3D structure of acetylcholinesterase using GLIDE. The docked phytocompounds are compared with the synthetic drug Rivastigmine. The compounds with better results than the drug were identified based on Glide Score (G-Score) and tabulated (Table 2 ). Glide Score is predicted based on the hydrophobic interactions, hydrophobically packed H-bonds, lipophilic, low molecular weight and electrostatic interactions. The interactions of the synthetic drug and phytocompounds with acetylcholinesterase are listed in Figure 2 (A-E). 
DISCUSSION
Alzheimer's disease, a neurodegenerative disease, is mainly associated with loss of cholinergic neurons in brain 20, 21 . acetylcholinesterase is a principal enzyme that hydrolysis acetylcholine which is involved in the development of AD 22 and has an independent action in the central nervous system 23 . They are mainly present in nervous tissue, muscles, plasma and blood cells 24 . Inhibition of this enzyme is the present senario for the AD treatment 25 . Tacrine, the first Acetylcholinesterase inhibitor approved by FDA in 1993 for the treatment of AD 26 , has been deregistered due to prominent hepatotoxicity. Rivastigmine, an effective synthetic drug with low risk of side effects 27 delays the breakdown of acetylcholine and enhances cholinergic neurotransmission. In modern world medicinal plants play a major role in the development of new drugs 28 and considered to be a primary health care system. Prasannakumar et al 29 reported the hypoglycemic action of the pectin isolated from the fruits of Coccinia indica. β-sitosterol, taraxerone and retinol are the major compounds isolated from the fruit of Coccinia grandis 30 . β -Sitosterol, a phytosterol isolated from the fruit of Coccinia grandis showed anti hepatotoxic activities on serum transaminases and hepatic antioxidant enzymes in CCl 4 intoxicated rats 31 . The compound also possesses antibacterial and antioxidant activity 32 . Due to the incorporation of β-sitosterol into cell membrane, glucose oxidase-induced oxidative stress and lipid peroxidation was prohibited and this compound is useful to treat neurodegenerative disorders like Alzheimer disease 33 . Retinol possesses antibacterial 34 , anti-inflammatory and antioxidant activity 35 . The compounds pectin and retinol have been reported to possess in silico anti-atherosclerotic activity 36 . Taraxerone, a pentacyclic triterpenoid compound was isolated from the ethyl acetate extract of Sedum sarmentosum showed high antioxidant activity 37 . The methanolic leaf extracts of Strobilanthes crispus L showed acetylcholinesterase inhibitory activities which may be due to the presence taraxerone in the plant 38 . Antioxidant plays a potential role in the AD patients due to the accumulation of free radical in brain and existence of oxidative stress [39] [40] [41] . The methanolic extract of the Coccinia grandis fruit possess antioxidant activity 15 which may be due to the presence of β-sitosterol, pectin, retinol and taraxerone compounds in the fruit. The in silico evaluation of these compounds showed better acetylcholinesterase inhibition activity, a key enzyme for the treatment of AD. Further, it is concluded that the compounds β-sitosterol, pectin, retinol and taraxerone which are from the fruits of Coccinia grandis can be used as lead molecule in the treatment of AD for avoiding side effects. As the fruit is commonly available and edible, this can be a nutraceutical to reduce the severity and progress of Alzheimer's disease.
